The launch comes after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumors exhibiting a rearranged during transfection (RET) gene, as stated by the company.
Tanstrive is offered in India in tablet strengths of 40 mg, 80 mg, 120 mg, and 160 mg; to be taken orally twice a day. The price is set at ₹2.15 lakh per box, covering a 14-day treatment regimen with doses administered twice daily, according to the company.
Also read: Bain Capital exits Emcure Pharma after selling remaining stake, ends 12-year bet
It is designed to specifically target RET alterations and inhibit the abnormal signaling pathways that promote tumor growth.
Being an oral therapy taken twice a day, Tanstrive provides a targeted treatment option for eligible patients whose cancers are driven by RET alterations, as per the company’s statement.
”As precision oncology continues to advance cancer care, Tanstrive signifies a significant leap forward — broadening access to targeted therapies for patients in India,” stated Winselow Tucker, President and General Manager of Eli Lilly and Company (India).
(Edited by : Gareema Bangad)
